Tokyo, Japan and Cambridge and London, UK, 17 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) and Cancer Research UK announce that the first patient has been dosed in a Phase 2a clinical trial (NCT05944237) evaluating Nxera’s investigational immunotherapy drug HTL0039732 (also known as NXE0039732) for advanced solid tumors.
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
Seeking Alpha / 1 hour from now 1 Views
Comments